Sonneveld, P., Moreau, P., Dimopoulos, M. A., Quach, H., Ho, P. J., Beksac, M., . . . Rodriguez-Otero, P. (2024). MM-355 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study. Clinical Lymphoma, Myeloma and Leukemia, 24(Supplement 1), S550. https://doi.org/10.1016/S2152-2650(24)01669-0

Sonneveld, Pieter, et al. "MM-355 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study." Clinical Lymphoma, Myeloma and Leukemia 24, no. Supplement 1 (2024): S550. https://doi.org/10.1016/S2152-2650(24)01669-0.

Sonneveld, Pieter, et al. "MM-355 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study." Clinical Lymphoma, Myeloma and Leukemia, vol. 24, no. Supplement 1, 2024, p. S550, https://doi.org/10.1016/S2152-2650(24)01669-0.